FDA conditionally approves Liavium-CA1 for canine CM/SM pain
Bottom line
FDA has conditionally approved Liavium-CA1, a pregabalin chewable tablet from TriviumVet/Pegasus Laboratories, for managing pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs. The May 12 approval makes it the first FDA-approved veterinary product specifically labeled for this indication, a serious neurologic condition seen most often in toy and small breeds, especially Cavalier King Charles Spaniels. Under the label, Liavium-CA1 is given orally twice daily with food at 5 to 10 mg/kg, may be used alongside an NSAID, and is available by prescription only; dogs under 3 kg can't be accurately dosed with the tablets. Because this is a conditional approval, FDA found the product safe and supported by a reasonable expectation of effectiveness, while the sponsor has up to five years to complete the data package needed for full approval. (fda.gov)
Why it matters: For veterinary professionals, this shifts pregabalin for CM/SM from a largely off-label tool to an FDA-reviewed, labeled option in a disease area where diagnosis is difficult and approved therapies have been absent. FDA's Freedom of Information summary says the approval relied on published clinical studies and safety work, including evidence that pregabalin at 5 mg/kg twice daily with an NSAID reduced pain scores and clinical signs in affected dogs, while higher-dose literature helped set the upper end of dosing because adverse effects such as sedation, ataxia, somnolence, increased appetite, and increased water intake became more prominent. The product is also a Schedule V controlled substance, which adds prescribing and record-keeping considerations for clinics. (animaldrugsatfda.fda.gov)
What to watch: Next comes commercial rollout, post-marketing monitoring, and the sponsor's progress toward the effectiveness data FDA will require for full approval within the conditional approval window. (fda.gov)
Key facts
- Product
- Liavium-CA1
- Active ingredient
- Pregabalin
- Dosage form
- Chewable tablet
- Indication
- Management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs
- FDA action date
- May 12, 2026
- FDA status
- Conditionally approved
- Firsts
- First FDA-approved veterinary product specifically labeled for this indication
- Dose
- 5 to 10 mg/kg by mouth twice daily with food
- Limitations
- Dogs under 3 kg cannot be accurately dosed with the tablets
The FDA has conditionally approved Liavium-CA1, a pregabalin chewable tablet for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs, giving veterinarians the first FDA-reviewed product specifically labeled for this niche but clinically significant neurologic syndrome. The agency announced the decision on May 12, 2026, and said the drug qualified because CM/SM is serious, there was no approved animal drug already marketed in the U.S. for this use, and proving effectiveness requires difficult studies tied to advanced imaging and disease-specific endpoints. (fda.gov)
That background matters. CM/SM has long been challenging to diagnose and manage in practice, in part because signs can be vague, intermittent, and easily mistaken for dermatologic, orthopedic, behavioral, or age-related problems. FDA describes the disorder as a structural neurologic syndrome in which a skull that's too small for the brain contributes to cerebellar crowding and disrupted cerebrospinal fluid flow, producing painful syrinxes in the spinal cord. Review articles in the veterinary literature have similarly noted that wider MRI access improved recognition of the disease and that medical management has often centered on neuropathic pain control with gabapentin or pregabalin, even before any labeled product existed. (fda.gov)
The approval specifics are practical for clinics. According to FDA's FOI summary, Liavium-CA1 is supplied as 30 mg, 90 mg, and 180 mg chewable tablets in 60-count bottles, with the 90 mg tablet scored for splitting. The labeled dose is 5 to 10 mg/kg by mouth twice daily with food, and the product may be given concurrently with an NSAID. Dogs under 3 kg can't be accurately dosed with the tablets. The sponsor listed in the FDA filing is TriviumVet of Ireland, while Pegasus said in its announcement that it acquired TriviumVet in 2025 and plans U.S. availability in beef-flavored tablet strengths for dogs weighing about 6.6 to 50 pounds. Pegasus also noted that pregabalin is a Schedule V controlled substance, so federal and state controlled-substance rules apply. (animaldrugsatfda.fda.gov)
FDA's evidence summary offers a clearer look at what supported the decision. For reasonable expectation of effectiveness, the agency relied on a published crossover study in nine client-owned Cavalier King Charles Spaniels with symptomatic CM/SM, in which pregabalin at 5 mg/kg twice daily, given with an NSAID, lowered owner-assessed pain scores and improved some quantitative sensory testing measures versus placebo. A second published study in 12 Cavaliers helped define the upper end of dosing, but adverse reactions at higher exposures led FDA, with veterinary neurology input, to cap the label at 10 mg/kg twice daily. In the FOI summary, sedation was reported in two dogs in the first study, while the second study described reduced activity, ataxia, increased appetite, somnolence, and increased water intake more often with pregabalin than placebo. A separate 90-day margin-of-safety study in Beagles found glycosuria without hyperglycemia and dose-dependent hypothermia. (animaldrugsatfda.fda.gov)
Industry reaction has centered on access and recognition. In Pegasus' release, Senior Director of Medical Affairs and Veterinary Services Heather Davis, DVM, PhD, DACVS-LA, called Liavium-CA1 "a first-of-its-kind option" for neuropathic pain management in affected dogs. The company also framed the approval as a way to bring a regulated product to a condition that has "flown under the diagnostic radar." That theme lines up with broader veterinary commentary: Today's Veterinary Practice has described CM/SM as a disorder that was likely underdiagnosed before advanced imaging became more available, and noted that pregabalin has been part of medical management discussions for years. (prnewswire.com)
Why it matters: For veterinary professionals, the biggest shift is less about a brand-new mechanism than about regulatory clarity and standardization. Pregabalin has been familiar in referral neurology, but this approval gives general practitioners and specialists a labeled formulation, defined dosing range, FDA-reviewed safety information, and a clearer framework for discussing expectations with pet parents. It may also sharpen case recognition: FDA and Pegasus both emphasized that hallmark signs such as phantom scratching, vocalization, and head or neck sensitivity are often misread, particularly in small and toy breeds. At the same time, the conditional pathway is an important caveat. FDA has not yet granted full approval; it has determined that the drug is safe and has a reasonable expectation of effectiveness, with more confirmatory data still required. Clinics will also need to weigh sedation and ataxia risk, controlled-substance handling requirements, and the practical limitation that very small dogs under 3 kg aren't candidates for accurate tablet dosing. (fda.gov)
What to watch: The next milestones are commercial launch, uptake in neurology and primary care, adverse-event reporting, and whether TriviumVet/Pegasus can convert conditional approval to full approval within the allowed renewal period of up to five years. It will also be worth watching whether the product changes referral patterns for MRI-confirmed CM/SM, or broadens treatment conversations earlier in the diagnostic workup for predisposed breeds. That last point is an inference based on the FDA's emphasis on diagnostic complexity and the long-standing underrecognition described in veterinary literature. (fda.gov)